 Westport, Connecticut--Newsfile Corp. - June 24, 2021 - Portage Biotech Inc. NASDAQ: PRTG Portage or the Company a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that it has priced its previously announced underwritten public offering of 1,000,000 ordinary shares. The public offering price of each ordinary share is 23.00. In addition, Portage has granted the underwriters a 30-day option to purchase up to an additional... 